Rain Therapeutics is a clinical-stage precision oncology company, with the mission to develop the best precision oncology therapies for patients suffering from cancer.
Total raised: $118M
Founded date: 2017
Investors 2
| Date | Name | Website |
| 19.11.2020 | Logos Capi... | logoscapit... |
| - | Perceptive... | perceptive... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.04.2021 | IPO | $100M | - |
| 21.05.2018 | Series A | $18M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 04.09.2020 | Rain bags $63M, ex-Daiichi cancer drug to mount pivotal push | Rain Therapeutics has raised $63 million and licensed a Daiichi Sankyo cancer drug to accelerate its... | fiercebiot... |
| 04.09.2020 | Rain bags $63M, ex-Daiichi cancer drug to mount pivotal push | Rain Therapeutics has raised $63 million and licensed a Daiichi Sankyo cancer drug to accelerate its... | fiercebiot... |
| 21.05.2018 | Rain Therapeutics scores $18 million Series A round for lung... | Rain plans to use its funding to start a Phase II clinical trial of tarloxotinib in the first half o... | medcitynew... |
| - | Rain Therapeutics scores $18 million Series A round for lung... | A company developing a drug for a hard-to-treat form of lung cancer has secured a funding round wort... | medcitynew... |